Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications

Movement Disorders

Volumn 31, Issue 8, 2016, Pages 1183-1191

  Dams, Judith ^a   Balzer Geldsetzer, Monika ^a   Siebert, Uwe ^b,c,d   Deuschl, Günther ^e   Schuepbach, W M Michael ^f,k,l,m   Krack, Paul ^g   Timmermann, Lars ^h   Schnitzler, A ⁿ   Reese, Jens Peter ^a   Dodel, Richard ^a,j   Schuepbach, W M M ⁿ   Rau, J ⁿ   Knudsen, K ⁿ   Volkmann, J ⁿ   Krack, P ⁿ   Timmermann, L ⁿ   Halbig T D ⁿ   Hesekamp, H ⁿ   Navarro, S M ⁿ   Meier, N ⁿ   Falk, D ⁿ   Mehdorn, M ⁿ   Paschen, S ⁿ   Maarouf, M ⁿ   Barbe, M T ⁿ   Fink, G R ⁿ   Kupsch, A ⁿ   Gruber, D ⁿ   Schneider, G H ⁿ   Seigneuret, E ⁿ   Kistner, A ⁿ   Chaynes, P ⁿ   Ory Magne, F ⁿ   Brefel Courbon, C ⁿ   Vesper, J ⁿ   Wojtecki, L ⁿ   Houeto, J L ⁿ   Bataille, B ⁿ   Maltete D ⁿ   Damier, P ⁿ   Raoul, S ⁿ   Sixel Doering, F ⁿ   Hellwig, D ⁿ   Gharabaghi, A ⁿ   Kruger R ⁿ   Pinsker, M O ⁿ   Amtage, F ⁿ   Regis J M ⁿ   Witjas, T ⁿ   Thobois, S ⁿ   Mertens, P ⁿ   Kloss, M ⁿ   Hartmann, A ⁿ   Oertel, W H ⁿ   Post, B ⁿ   Speelman, H ⁿ   Agid, Y ⁿ   Schade Brittinger, C ⁿ   Deuschl, G ⁿ   more..

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF KIEL   (Germany)

^f UNIVERSITY OF BERN   (Switzerland)

^g INSERM   (France)

^h UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

ⁱ HEINRICH HEINE UNIVERSITY   (Germany)

^j UNIVERSITY OF DUISBURG ESSEN   (Germany)

^k INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^l Assistance Publique de Paris   (France)

^m SORBONNE UNIVERSITÉ   (France)

ⁿ NONE

more..

Author keywords

cost utility analysis; deep brain stimulation; dyskinesia; early Parkinson's disease; Markov model

Indexed keywords

ARTICLE; BRAIN DEPTH STIMULATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE SYSTEM; HIDDEN MARKOV MODEL; HUMAN; MOTOR DYSFUNCTION; NERVE STIMULATION; NEUROLOGIC DISEASE ASSESSMENT; PARKINSON DISEASE; PARKINSON DISEASE QUESTIONNAIRE 39 SUMMARY INDEX; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SUBTHALAMIC NUCLEUS; UNCERTAINTY; ADULT; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; GERMANY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROCEDURES; QUALITY OF LIFE;

ANTIPARKINSON AGENT;

ADULT; ANTIPARKINSON AGENTS; COST-BENEFIT ANALYSIS; DEEP BRAIN STIMULATION; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; QUALITY OF LIFE; SUBTHALAMIC NUCLEUS;

EID: 84981187581     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26740     Document Type: Article

References (35)

1. DeuschlG, Oertel W, Reichmann H, et al. German guideline for idiopathic Parkinson's disease [Leitlinie Idiopathisches Parkinson Syndrom]. Available from: https://www.awmf.org
2. Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 2011;68:165.
3. Deuschl G, Schupbach M, Knudsen K, et al. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord 2013;19:56-61.
4. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013;368:610-622.
5. Deuschl G, Schade Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908.
6. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006;21(Suppl 14):S290-S304.
7. Weaver F, Follett K, Hur K, et al. Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurosurg 2005;103:956-967.
8. Dams J, Siebert U, Bornschein B, et al. Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease. Mov Disord 2013;28:763-771.
9. Walter E, Odin P. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany. J Med Econ 2015;18:155-165.
10. National Collaborating Centre for Chronic Conditions. Parkinson's disease: national clinical guideline for diagnosis and management in primary and secondary care. Appendix F. London: Royal College of Physicians; 2006.
11. Eggington S, Valldeoriola F, Chaudhuri KR, Ashkan K, Annoni E, Deuschl G. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease. J Neurol 2013;261:106-116.
12. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. J Neurol 2001;57:663-671.
13. Valldeoriola F, Morsi O, Tolosa E, Rumia J, Marti MJ, Martinez-Martin P. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease. Mov Disord 2007;22:2183-2191.
14. Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making 2012;32:667-677.
15. Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making 2012;32:690-700.
16. Spottke AE, Reuter M, Machat O, et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 2005;23:817-836.
17. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization?. Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-481.
18. Martilla R, Rinne UK. Disability and progression in Parkinson's disease. Acta Neurol Scand 1977;56:159-169.
19. Statistisches Bundesamt. Life table Germany 2009-2011. 2013. [cited 2011 27 Mar] Available from: https://www.destatis.de
20. Wermuth L, Stenager EN, Stenager E, Boldsen J. Mortality in patients with Parkinson's disease Acta Neurol Scand 1995;92:55-58.
21. Krack P, Batir A, van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349:1925-1934.
22. Valldeoriola F, Pilleri M, Tolosa E, et al. Bilateral subthalamic stimulation monotherapy in advanced Parkinson's disease: long-term follow-up of patients. Mov Disord 2002;17:125-132.
23. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301:63-73.
24. Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London. BMJ 2000;321:21-22.
25. Medtronic (Economia). Neuromodulation. Coding and remuneration in inpatient care [Neuromodulation. Kodierung und Vergütung in der stationären Versorgung]. Meerbusch: Medtronic; 2013.
26. Anheim M, Fraix V, Chabardes S, Krack P, Benabid AL, Pollak P. Lifetime of Itrel II pulse generators for subthalamic nucleus stimulation in Parkinson's disease. Mov Disord 2007;22:2436-2439.
27. Ondo WG, Meilak C, Vuong KD. Predictors of battery life for the Activa Soletra 7426 neurostimulator. Parkinsonism Relat Disord 2007;13:240-242.
28. Greiner W, Hoffmann C. Guidelines for health economic evaluation. Approaches and methods of economic evaluation – an international perspective [Leitlinien zur gesundheitsökonomischen Evaluation. Ansätze und Methoden der ökonomischen Evaluation—eine internationale Perspektive]. Baden-Baden: Nomos; 1999.
29. Young MK, Ng SK, Mellick G, Scuffham PA. Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson's disease. Qual Life Res 2013;22:1065-1072.
30. Institute for Quality and Efficiency in Health Care (IQWiG). Methods for assessment of the relation of benefits to costs in the German statutory health care system. 2008. [cited 2010 27 Mar]. Available from: https://www.iqwig.de
31. Dams J, Klotsche J, Bornschein B, et al. Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease. Health Qual Life Outcomes 2013;11:35.
32. Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000;15:1112-1118.
33. Dams J, Bornschein B, Reese JP, Conrads-Frank A, Siebert U, Dodel R. Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review. Pharmacoeconomics 2011;29:1025-1049.
34. Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008;7:605-614.
35. Gonzalez V, Fluck L, Topouchian A, et al. Cost analysis of rechargeable deep brain stimulator in surgery dystonia-dyskinesia syndrom (DDS). Mov Disord 2014;29(Suppl 1):1368.